Imugene and RenovoRx CF33 Virotherapy Delivery Collaboration
Filed with ASX · · 5 pages · English
In the deck
Story so far
Earlier from Imugene
- Imugene Oncolytic Virotherapy CF33 Patent Allowed in the US
- New Dose Escalation in Phase I Clinical Trial of CHECKvacc
- HER-Vaxx induced antibodies correlated with tumour reduction
- Imugene PD1-Vaxx patent extended to 2040
- Imugene Advances VAXINIA MAST Trial to Next IV Cohorts
Later from Imugene
- Imugene HER-Vaxx and CHECKVacc to be Featured at ESMO
- Imugene CF33 Oncolytic Virus Study to be Showcased at SITC
- Imugene VAXINIA Trial clears Cohort 3 of IT Monotherapy
- Imugene Licenses Allogeneic CD19 CAR T Cell Therapy
- Imugene completes $35M Placement & Launches c.$30M SPP
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene